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AbstrACt
Introduction The benefits of palliative care rely on how 
healthcare professionals assess patients’ needs in the 
initial encounter/s; crucial to the design of a personalised 
therapeutic plan. However, there is currently no evidence- 
based guideline to perform this needs assessment. We 
aim to design and evaluate a proactive and systematic 
method for the needs assessment using quality guidelines 
for developing complex interventions. This will involve 
patients, their relatives and healthcare professionals in all 
phases of the study and its communication to offer clinical 
practice a reliable approach to address the palliative needs 
of patients.
Methods and analysis To design and assess the 
feasibility of an evidence- based, proactive and systematic 
Multidimensional needs Assessment in Palliative care 
(MAP) as a semistructured clinical interview guide 
for initial palliative care encounter/s in patients with 
advanced cancer. This is a two- phase multisite project 
conducted over 36 months between May 2019 and May 
2022. Phase I includes a systematic review, discussions 
with stakeholders and Delphi consensus. The evidence 
gathered from phase I will be the basis for the initial 
versions of the MAP, then submitted to Delphi consensus 
to develop a preliminary guide of the MAP for the 
training of clinicians in the feasibility phase. Phase II is 
a mixed- methods multicenter feasibility study that will 
assess the MAP’s acceptability, participation, practicality, 
adaptation and implementation. A nested qualitative study 
will purposively sample a subset of participants to add 
preliminary clues about the benefits and barriers of the 
MAP. The evidence gathered from phase II will build a MAP 
user guide and educational programme for use in clinical 
practice.
Ethics and dissemination Ethical approval for this 
study has been granted by the university research ethics 
committee where the study will be carried out (approval 
reference MED-2018-10). Dissemination will be informed 
by the results obtained and communication will occur 
throughout.
IntroduCtIon
Palliative care (PC) was originally conceived 
to address the suffering of those dying from 
advanced disease such as cancer,1 2 but has 
evolved to providing early PC from diagnosis 
strengths and limitations of this study
 ► This study intends to use guidance from the de-
velopment of complex interventions, employing 
stages for informed development and subsequent 
implementation of a needs assessment in the first 
encounter of palliative care, to establish a valid and 
reliable method for the evaluation of patients.
 ► Data will be collected from patients, relatives and 
professionals throughout to ensure representative 
integration of all stakeholders invested in palliative 
care outcomes.
 ► Both qualitative and quantitative methods are used 
to inform theory and describe feasibility for use in 
actual palliative care clinical practice.
 ► A feasibility trial will evaluate the needs assessment 
in clinical practice using mixed methods as well as 
report a process evaluation to inform both refine-
ment for future clinical trial and palliative care re-
search of benefits and challenges involved.
 ► The study is limited to being carried out throughout 
regions of Spain, which may not generalise to other 
clinical contexts and/or professional culture, as does 
only recruiting patient with advanced cancer and 
their families, which limits generalisability to other 
palliative populations.
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of advanced cancer, and through the trajectory including 
bereavement.3–5 It is estimated that 69%–82% of cancer 
deaths would benefit from PC,6 which can improve 
quality of life,7 patient8 and caregiver distress9 and even 
survival.10 As a result, there have been multiple calls for 
the integration of PC into standard oncology care to 
achieve best outcomes.11–14 With this greater demand for 
PC to improve cancer care throughout the disease trajec-
tory, it is crucial to ensure clinical practice is prepared to 
understand and address the palliative needs of patients 
with cancer and their families.
The WHO defines the success of PC to improve 
quality of life ‘by means of early identification and 
impeccable assessment’.15 An assessment of needs 
at the initial palliative encounter is therefore para-
mount, yet there are no guidelines or evidence- based 
standards for this critical aspect of care. Without 
evidence to guide PC practice, healthcare providers 
often defer to anecdotal or professional experience,16 
which ultimately undermines equitable and compre-
hensive patient care.17 18 Clearly, a better approach 
to the comprehensive assessment of PC needs is 
urgently required, using evidence- based methods 
that are supported by standards of high- quality cancer 
care.17 19
Evidence suggests providers lack consensus on the 
multiple dimensions that appropriately assess PC needs 
according to patient and family member perspectives. 
According to the WHO, minimum goals of PC include 
assessment of physical, psychosocial and spiritual prob-
lems.15 Meanwhile, a review of PC literature showed 
62% of studies in the field limited their focus to phys-
ical or psychosocial symptoms.20 Given that unmet needs 
are associated with increased healthcare costs21 and 
increased distress, which can reduce survival,7 22 the goals 
of PC should be to ensure that all possible dimensions are 
assessed in an efficient way.
Current research also overwhelmingly shows that assess-
ments are based on tools,23 that are neither personalised 
nor implemented for practice. Tools focus on merely 
identifying needs, but cannot permit the patient or family 
to express and explore issues with provider, nor replace a 
meaningful initial encounter that builds the therapeutic 
alliance.24 Self- report tools place the burden on the 
patient, but the patient cannot always communicate what 
their care priorities are without empathic feedback.25 
What is needed is evidence for a feasible and efficient 
(being thorough in an acceptable amount of time) semi-
structured clinical interview guide for the comprehen-
sive needs assessment that providers can implement in 
practice.
A further issue is with the quality of evidence in service 
of clinical guidelines for PC. In 2009, the topic of PC was 
covered by <1% of cancer research.20 The level of research 
evidence has been deemed as low- quality evidence in 
various aspects of PC.26 27 And two systematic reviews 
highlighted that palliative research is overwhelmed with 
surveys and descriptive studies.20 27 Thus, the field is 
stunted by the lack of analytical studies that can inform 
practice guidelines.
The current protocol seeks to overcome the abovemen-
tioned limitations and challenges, aiming to develop and 
test the feasibility of an evidence- based proactive multi-
dimensional efficient needs assessment in the initial 
encounter/s with PC. The goal is to design comprehen-
sive and individualised care plans that will ensure equity 
in healthcare. We seek to guide and to advance clinical 
practice and therefore call this approach ‘MAP: proactive 
and systematic Multidimensional needs Assessment in 
Palliative care’. In addition, the knowledge gathered from 
the research programme will be the basis for an educa-
tional programme on needs assessment in PC that will be 
offered to the PC oncology community. This study will lay 
the groundwork for a future randomised controlled trial 
(RCT).
objective
This multicenter study aims to design and implement a 
complex intervention that will proactively and systemat-
ically assess the multidimensional needs of patients with 
advanced cancer and their families when first assessed by 
a PC team.
study setting
Nine different centres will participate and recruit 
patients. Five are public health university hospitals, two 
concerted- public health university hospitals, one private 
university hospital and a concerted- public health long- 
term hospital.
PAtIEnt And PublIC InvolvEMEnt
Patients and the public were not involved in the 
design of the complex intervention; however, patients 
and their relatives will be involved throughout both 
phases to inform the development and feasibility of 
the MAP. The nature of the MAP is to explore and 
address the needs of patients, thus patient feed-
back is likewise included to assess the burden of the 
MAP, rating its acceptability and that it is not time- 
consuming, during phase II. Plans to communicate 
project goals and findings are aimed at engaging 
the public with the study objectives and preliminary 
results through a website along with a twitter account 
with specific hashtag designed to communicate prog-
ress throughout the development of MAP.
MEthods And AnAlysIs
The study is guided by an established framework for 
developing complex interventions,28 and is divided into 
two phases (figure 1): phase I will gather evidence to 
inform the design of the proactive and systematic MAP. 
Phase II will test the feasibility and acceptability of the 
MAP in a mixed- methods prospective cohort study. The 
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Figure 1 Study design phases of development and 
evaluation of the MAP toward a future intervention to be 
tested in a RCT. MAP, Multidimensional needs Assessment in 
Palliative care; RCT, randomised controlled trial.
Table 1 Study population criteria for phase I, stage 2
Inclusion Exclusion
All participants Age ≥18 Age <18
Speak and understand Spanish or Catalan   
Cognitive capacity to communicate clearly   
Freely accept participation in the study and sign informed consent   
Patients Advanced illness   
Receiving PC   
ECOG status 0–3   
Inpatient or outpatient Patients receiving PC at home
Without cognitive failure ≥5 fails on Pfeiffer questionnaire52
Relatives Caregiver responsible for patient   
Present at initial visit of patient from PC   
Familiar with diagnosis and prognosis of patient   
Professionals PC doctors or nurses with an active role in the assessment of the 
patient in PC
  
ECOG, Eastern Cooperative Oncology Group; PC, palliative care.
study will be conducted over 36 months from May 2019 
to May 2022.
Phase I—gather evidence to inform the design of the 
proactive and systematic MAP
Objectives
To define, develop and reach consensus on the design of 
the MAP in three stages:
1. Stage 1—identifying the evidence base.
2. Stage 2—developing theory.
3. Stage 3—modelling process and outcomes.
Stage 1: identifying the evidence base
Objective: To perform an integrative systematic review of 
the methods used in the PC literature for the assessment 
of needs and whether they correspond to all multidimen-
sional needs reported by patients.
Procedure: An integrative systematic review of the 
literature began in May 2019 according to the require-
ments of the Preferred Reporting Items for Systematic 
review and Meta- Analysis Protocols guidelines.29 Details 
are submitted as a protocol in PROSPERO (International 
prospective register of systematic reviews). Following data 
extraction from the full- text stage, and an integrative 
method of analysis by the team,30 a semistructured inter-
view guide will be developed for Stage 2. This integrative 
review uses a data reduction method, clustering original 
articles according to a developed coding scheme that 
summarises similarities or patterns between data derived 
from different methodologies (ie, quantitative, quali-
tative, mixed methods). Because the goal is to use this 
method to look for similarities according to the needs 
reported and assessed in the literature, the analysis will 
inform the interview guide with open- ended questions 
that probe the broad areas of need (eg, specific physical 
or psychological symptoms) found to be relevant from 
the review. The aim will be to explore the key issues that 
appear in the literature, to allow participants to define 
how these needs relate to their perceived needs and 
develop an understanding of their care priorities in an 
open discussion.
Stage 2: developing theory
Objective: To engage discussions with key stakeholders 
(individual semistructured interviews with patients and 
their relatives, a nominal group with healthcare profes-
sionals) to develop knowledge and build a framework of 
how to proactively and systematically assess the needs of 
patients in PC.
Eligibility criteria
Eligibility criteria for all participants, as well as pertaining 
specifically to the patients, relatives and professionals, are 
summarised in table 1.
sample size
Semistructured interviews with patients and relatives
PC teams from participating centres will offer consecu-
tive patients participation in the study, who will be asked 
if they have a family member interested in participating. 
Individual in- depth interviews will be carried out with 
10–12 patients with cancer and 10–12 relatives, separately. 
The number of participants is estimated based on recom-
mendations in the qualitative literature to focus not on 
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number of participants but the adequacy of information 
obtained from interviews.31 Thus, this sample size reflects 
a range that is recommended as adequate to achieve 
data saturation; that is, the point where themes from any 
further participant would be redundant.32 33
Nominal group with healthcare professionals
In November 2018, in the context of a workshop we 
formed a work group with PC expert clinicians and 
researchers from 12 institutions throughout Spain (Barce-
lona, Girona, Lleida, Madrid, Pamplona and Tarragona). 
The nominal group will be constituted of, among others, 
these PC experts from various disciplines: nurses, physi-
cians, psychologists and social workers. All experts who 
participate will have (1) more than 5 years of experience 
in PC and/or (2) be hospital service chiefs of PC. The 
group size of 12 is consistent with the literature using the 
nominal technique (for review see McMillan et al34), and 
is sufficient in this context given it exceeds recommenda-
tions of only seven per group.35
Procedure
Researchers trained in qualitative methods will lead the 
interviews and nominal groups. To maintain objectivity, 
these researchers will not be involved in patient care 
nor study design. Furthermore, the participants will be 
encouraged to comment on any aspect relevant to them, 
acknowledging there are no right or wrong responses 
expected from the interviewer. Finally, results will be anal-
ysed by a team including researchers not involved in data 
collection to avoid possible bias.
Individual semistructured interviews
Two researchers will lead individual interviews using a 
semistructured interview guide focusing on multidimen-
sional needs of patients receiving PC. Opinions will be 
explored through a guided discussion about the needs 
assessment they experienced and what ways they felt satis-
fied or would make recommendations for improvement.
Nominal group
Face- to- face discussions will occur after the following four 
stages of the nominal group: (1) generating ideas, (2) 
discussion, (3) summary and conclusions and (4) ranking 
or individual prioritisation.34
Data analysis
The semistructured interviews will be audio- recorded 
and transcribed verbatim. Thematic analysis of the data 
will be performed.36 37 Scores based on rankings from 
the nominal group will be recorded into Microsoft Office 
Excel (version 16.31) spreadsheets. We will calculate the 
sum of the scores for each idea and frequency of votes to 
create a list of priorities in order of highest frequency.
Stage 3: modelling process and outcomes
Objective: To draft the MAP as a semistructured clin-
ical interview guide for PC practice and evaluate the 
relevance of the preliminary version according to 
experts in PC.
Procedure: By means of the information from the semi-
structured interviews and nominal group with patients, 
relatives, PC professionals, a preliminary version of the 
MAP will be developed. The focus of development of the 
MAP will be to create a semistructured interview guide 
for clinical practice, which will provide a systematic way 
to ensure inquiry into the necessary topics that are most 
relevant for the patient.
To develop the interview guide that those in the 
field of PC would use in clinical practice, we will seek 
consensus from a larger group of 30 to 40 national 
experts about the contents of the MAP using the Delphi 
technique.38 Participants in the Delphi process will be 
selected by means of intentional sampling from partici-
pating centres with at least one of the following criteria: 
health professionals with clinical experience in the 
field of PC, and/or researchers with knowledge and/
or experience related to the patients’ assessment in 
PC. In order to achieve a high- quality Delphi process, 
a heterogeneous group of experts will be recruited, 
selected from across various geographical regions and 
from different professional fields. Potential participants 
will be contacted by email and informed about the aims 
of the study, the tasks involved and the estimated neces-
sary time commitment. The experts who agree to partic-
ipate will provide responses through sequential online 
questionnaires completed individually and anony-
mously until consensus is reached. The key strengths of 
this approach are the anonymity of participants, struc-
turing of the information flow and provision of regular 
feedback coordinated by the research team. The ques-
tionnaire will be formed by using statements that break-
down each of the topics and questions that comprise 
this preliminary version of the MAP.
For each statement, each participant has to rate 
their agreement on a five- point scale (5=strongly 
agree to 1=strongly disagree). Space is also provided 
for participants to make comments and/or suggest an 
alternative. We will carry out a number of rounds until 
a consensus is reached (approximately 2–3). In the 
first round, each concept must achieve a rating of ≥4, 
which according to established methods,34 must reach 
a consensus of 80% to be accepted and included in the 
second round for rerating of items. The first round 
also serves to determine if any changes to wording 
of statements are required for re- evaluation. In the 
second round, each participant receives only the 
statements that reached consensus, along with person-
alised information regarding their previous rating for 
each statement and the comments provided by others 
for reference. If all statements do not achieve 80% 
agreement, this step is repeated in a third round for 
further and final consensus on what statements will be 
included in the version of the MAP that professionals 
will receive training on for feasibility testing in the 
next phase.
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Table 2 Intervention eligibility criteria
Inclusion Exclusion
Advanced cancer13
Age ≥18 years Age <18 years
ECOG performance status 0–3
Inpatients or outpatients Home care patients
No cognitive failure ≥5 fails on Pfeiffer’s 
questionnaire52
Referred to PC
ECOG, Eastern Cooperative Oncology Group; PC, palliative care.
Table 3 Participant selection for the nested qualitative component of the intervention
Patients Purposively sampled from the feasibility trial considering different sociodemographic 
characteristics, health status, family support, etc, in order to achieve maximum variability.
Relatives The palliative healthcare professional will identify the relative who has been present during the MAP 
to participate.
PC health professionals Members of the PC services involved in carrying out the MAP will participate in focus groups.
MAP, Multidimensional needs Assessment in Palliative care; PC, palliative care.
data analysis
Data will be analysed by two members of the research 
team. Questionnaire responses will be entered into 
spreadsheets and will be calculated using the algo-
rithm proposed by Tastle & Wierman.39 This calcula-
tion provides the weighted targeted agreement for each 
statement, meaning statements rated as ‘4’ (ie, ‘agree’) 
and above are assigned higher weights and summarised 
as a percentage that are dispersed within that range of 
responses for each statement.
Once the MAP preliminary semistructured clinical 
interview guide is developed, the coordinators from each 
participating clinical centre, as well as the teams of PC 
professionals that will participate in the next phase of 
implementation of the MAP, will receive the appropriate 
training to homogenise its practice.
Phase II: a mixed-methods prospective cohort study
Objectives
To implement a multicenter complex intervention 
testing the feasibility of the newly designed MAP among 
PC patients, their families and healthcare professionals.
Eligibility criteria
Eligibility criteria are defined in table 2. Consecutive 
participants will be offered participation. All participants 
will have the study explained to them and we will obtain 
both verbal and written informed consent. Patients with 
advanced cancer are as defined by the American Society of 
Clinical Oncology: distant metastases, late- stage disease, 
cancer that is life limiting and/or with prognosis of 6 
to 24 months.13 Because we are interested in the initial 
encounter/s, we will not include home care patients, 
whom often have had prior contact with PC teams during 
previous hospital visits.
A nested qualitative study will be carried out, in which 
data- rich participants will be purposively sampled for 
interviews, to add preliminary clues about the benefits 
and barriers perceived by patients with advanced cancer 
who have been assessed with the MAP, one relative of 
the patient and PC health professionals in charge of 
conducting the MAP (table 3). All will be informed of 
the study to obtain verbal and written consent prior to 
participation.
Intervention
This is a mixed- methods phase II multicenter cohort 
study on the use of the MAP in patients with advanced 
cancer. It is conceived as an implementation feasibility 
study to be carried out in the initial clinical encounter/s 
with a specialised PC team.
Quantitative procedures
PC teams will implement the MAP defined and agreed 
on from development in phase I. The MAP may be 
integrated with standard oncological care or where 
PC is a main attending service. The PC team members 
conducting the MAP will introduce themselves as per 
usual, and will explain the nature of the procedure 
and its goals. Patients who give their consent to assess 
the feasibility of the MAP will be referred to a clinical 
encounter using the MAP (note that the final time 
assigned to the encounter will be decided as part of the 
consensus process of phase I). Some critically ill or frail 
patients could require to split the time into two evalua-
tions. Patients who do not give consent receive the usual 
assessment of PC.
sample size
It is an accepted standard in the literature that feasi-
bility studies, as trial runs, do not require power calcu-
lations.40 41 A sample size between 24 and 50 has been 
recommended.42–44 We will plan to recruit 34–35 eligible 
consecutive patients per center (total of 9 centers). This 
will provide a total sample size of 312 patients, and a 15% 
attrition rate based on the research teams’ experience, 
which estimates a final sample of approximately 265 
patients to exceed recommended sample sizes.
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Table 4 Quantitative outcomes and analyses to assess the feasibility of the MAP intervention
Outcomes Definition Measurement Criteria Analysis
Acceptability Patient’s opinions of the 
appropriateness of the 
MAP
Likert scale (0 completely 
inappropriate; 3 extremely 
appropriate).
≥75% patients score ≥2* Participants with 
rating ≥2 coded as ‘1’; 
else ‘0’. =(∑‘1’/N) *100
Participation Proportion of eligible 
patients with cancer who 
are assessed following 
the MAP
Number of patients who 
completed assessment via 
the MAP divided by the 
total number recruited and 
consented
≥75% of eligible patients are 
assessed
Eligibility rate:
# eligible (I); # 
consented (C) = (I/C) 
*100
Practicality Time for execution Time elapsed in minutes ≥75% of the MAP completed 
in the agreed on time from 
phase I
=Total min to 
complete MAP/
finalised agreed on 
time in minutes
Adaptation Clinician’s perceived 
acceptability for clinical 
utility
Likert scale (0 completely 
useless; 3 highly useful)
≥75% clinicians score ≥2 Participants with 
rating ≥2 coded as ‘1’; 
else ‘0’. =(∑‘1’/N) *100
Implementation The success of execution Researchers will check 
a standardised template 
of the encounter9 for 
completeness
≥80% of the dimensions of 
the MAP are covered in the 
clinical encounters
=Completion score 
from template *100; 
must be ≥80%
*Patient and relative’s acceptability will be reported (relative’s score will be considered as a secondary outcome).
MAP, Multidimensional needs Assessment in Palliative care.
Outcomes
Outcomes to assess feasibility are explained in table 4. 
These outcomes were chosen to explore feasibility as 
recommended by the literature.45
Statistical analysis
Analyses are outlined in table 4. Descriptive statistical anal-
yses done for feasibility data will be compared with feasi-
bility criteria values (eg, ≥75%) and reported as success or 
failure to meet criteria proposed. A subanalysis will provide 
a centre- by- centre comparison, with Analysis of variance 
(ANOVA) performed per criterion value between centres 
to determine statistically significant differences. Bonferroni 
post- hoc comparisons between centres will be carried out if 
an overall significant difference is observed.
Qualitative procedures
Participants who have participated in the quantitative 
portion of the feasibility study will be informed about 
the specific objectives of the qualitative interviews. Partic-
ipants’ attitudes towards participation in this additional 
phase of data collection will be queried.
Individual semistructured interviews will be carried out 
with patients and relatives separately. An interview guide 
will be developed aligning with the feasibility criteria to 
explore acceptability, perceived benefits and concerns and 
adaptation in the form of reactions to the content and 
process of the MAP. During the interview, the participants 
will be encouraged to comment on any aspect relevant to 
him. Interviews will be conducted by experts in qualitative 
research in three settings; three types of hospitals (public, 
private, concerted) in separate autonomous regions. The 
patient interviews will be conducted with 24–48 hours after 
having finished the MAP; and the relative interview as soon 
as possible after having conducted the patient interview to 
avoid data contamination through patient–family conver-
sations. Interviews will be audio- recorded and transcribed 
verbatim.
PC health professionals’ perspectives will be gathered 
through focus groups that will be conducted in participating 
settings by an expert in qualitative research. In total three 
focus groups will be carried out. Participants will be anony-
mised by assigning them a code. Focus groups will explore 
strengths and weaknesses of the MAP, with reference to 
both their view on patients’ and relatives’ reactions, and 
their own role within the study including the MAP delib-
eration and integration within available resources (practi-
cality) and setting context (adaptation). Focus groups will 
be audio- recorded and transcribed verbatim.
Sample size
Qualitative interviews
Patients. Data will be collected until saturation is reached. 
Sample size is estimated to be approximately 15–20 
patients, a documented sample size range that allows us to 
explore as many possible themes that arise as possible.46
Relatives. Data will be collected until saturation is 
reached. Sample size is again estimated to be approxi-
mately 15–20 relatives (one for each patient).
Healthcare professionals. As PC services usually consist of 
a limited number of health professionals, we expect that 
there will not be need to sample, as the whole sample 
will participate. Data will be collected until saturation 
is reached. In cases where there is a team that has many 
health professionals, different health professionals will be 
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Table 5 Process evaluation definition, outcomes and analyses
Acronym Focus Definition Measurement Analysis
R Reach Participation Consent rate defined as number 
of participants recruited/number 
of participants approached for 
participation
Analysis of variance on consent rate 
to determine differences between 
each centre*
E Efficacy Positive and Negative 
Reactions
Interview questions probing positive 
and negative responses to methods 
used from all stakeholders
Qualitative analysis according to 
themes of benefits or issues arising 
during intervention
A Adoption Different Settings’ 
ease of integration
Success rate defined as 
proportion=total number of patients 
who completed intervention/
intended N
Analysis of variance on success 
rates by centre to determine if any 
significant regional differences across 
settings exist*
I Implementation Adherence to 
protocol
Professional responses in 
qualitative interviews probing if any 
aspects were unclear or difficult to 
implement the intervention
Qualitative sub- analysis for themes 
that arise according to question 
regarding difficulties in use of the MAP
M Maintenance Intervention sustained 
over time
Mean recruitment rates (N per 
month) across centres for each 
month
Analysis of variance on mean 
recruitment rate, analysing differences 
in recruitment rate over time*
*Bonferroni post- hoc analysis carried out if significance observed.
MAP, Multidimensional needs Assessment in Palliative care.
purposefully selected up to a maximum of 10 participants 
in each setting.
Analysis. Thematic analysis36 37 of transcribed individual 
interviews and focus groups data will be conducted. To 
ensure the validity and reliability of the results, the data will 
be analysed independently by a qualitative expert familiar 
with the context of the data collection centre and another 
researcher. During data analysis, a consensus process 
between the researchers at the separate sites will devise a 
coding framework to review and guide the analysis of data 
and direct the thematic presentation of findings. Two 
workshops will be conducted during the analysis process 
to enhance adequate analysis process between researchers. 
The draft of the results will be shared across with the PC 
professionals involved on the MAP for their inputs and to 
ensure external validity. A 2- day workshop will be conducted 
with all the partners to reach a final agreement on the anal-
ysis results themes and culminate in the final reports.
Timeline
Data collection for the mixed- methods cohort study will 
occur over 26 months, from March 2020 through May 2021. 
The design of MAP will occur over months 1–10, training of 
professionals will occur between months 8 and 10, along-
side recruitment from months 8 to 16, followed by data 
analysis and preparation of manuscripts from months 16 
to 26.
ProCEss EvAluAtIon
In addition to feasibility study outcomes, and given calls 
to combine evaluation of outcomes with an evaluation of 
intervention process,47 we will perform a process evalua-
tion using the Reach, Efficacy, Adoption, Implementation, 
Maintenance (REAIM) model (table 5).48 Outcomes 
will be incorporated back into the development of the 
intervention by explaining whether or what changes to 
the MAP may be needed for a feasible use in practice. 
The process data will be reported with trial outcomes 
to generate hypotheses and research questions to be 
addressed for the future RCT.
EthICs And dIssEMInAtIon
Findings from the feasibility study and process evaluation 
will be used to inform appropriate dissemination strate-
gies. We will use an Evidence- based Model for the Transfer 
and exchange of Research Knowledge ‘EMTReK’,49 which 
is specifically designed to support knowledge transfer and 
exchange given the challenges of working with vulnerable 
populations in PC research.
dIsCussIon
This project aims to offer clinicians a proactive and 
systematic method for a multidimensional needs assess-
ment in the initial encounter/s, deemed acceptable by 
all its stakeholders. The development and evaluation of 
the MAP is guided by standards on how to build evidence 
towards long- term implementation of complex inter-
ventions.28 Given existing evidence alongside evidence 
collected from stakeholders, we anticipate the content 
of the MAP will adhere to other consensuses of best 
methods for a needs assessment in PC. This will include 
assessing multiple symptoms from multiple domains,50 
and allowing for open- ended questions that practitioners 
can flexibly adjust to each patient’s needs51 within a 
feasible and practical time frame. We will implement the 
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MAP in a small- scale study to examine feasibility that will 
allow us to evaluate and refine content towards evalua-
tion in a future RCT. In turn, this project aims to provide 
structured teaching courses on a multidimensional needs 
assessment in PC in the near future.
We propose that development of the MAP will respond 
to an urgent need to investigate the most effective but 
time- efficient method to assess multidimensional needs 
of patients with cancer. The objective is to bring equity to 
cancer care. By providing an evidence- based semistructured 
clinical interview guide, all healthcare providers can system-
atically and efficiently meet the demand for PC across the 
cancer continuum. This will advance scientific discovery to 
define the approaches that best fit the needs of patients and 
families.
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